Financial Data and Key Metrics Changes - Total Q4 revenue reached $11.3 million, representing a 37% year-over-year growth and a quarterly record, exceeding previous guidance [15][31] - Product revenue increased by 78% in Q4, driven by strong system placements, while consumable revenue grew by 11% [32][17] - Recurring revenue increased by 10% to $4.6 million, accounting for 53% of total revenue, indicating strong utilization of systems [17][34] - Q4 gross margin was impacted by inventory-related charges, resulting in a product margin of -8%, but excluding these charges, the margin was positive at 4% [34][36] - The net loss for Q4 was $12.5 million, compared to a net loss of $9.7 million in the same quarter last year [38] Business Line Data and Key Metrics Changes - 16 Growth Direct systems were placed in Q4, a record number, bringing the total to 190 systems globally, with 155 fully validated [15][31] - Consumable revenue for the full year increased by 17%, reflecting strong utilization across the installed base [17] - Service revenue in Q4 was $2 million, consistent with guidance, but lower than $3 million in Q4 2024 [32] Market Data and Key Metrics Changes - The partnership with MilliporeSigma is progressing well, with customer demo labs established across Europe and Asia to enhance sales efforts [20] - The expansion of the Growth Direct platform by Samsung Biologics highlights the demand for automation in pharmaceutical manufacturing [14][25] Company Strategy and Development Direction - The company aims to accelerate system placements, expand gross margins, and innovate new products while managing cash prudently [22][50] - A new cloud-native software platform is expected to be released in the second half of 2026, enhancing the Growth Direct experience and providing AI-driven analytics [27][100] - The company anticipates revenue guidance for 2026 to be between $37 million and $41 million, with expectations for gross margin expansion to approximately 20% [28][29] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term growth potential driven by increased automation adoption and a focus on data integrity in the pharmaceutical industry [25][26] - The company is optimistic about the contributions from the MilliporeSigma partnership and the ongoing demand for their systems in both principal manufacturers and CDMOs [23][60] Other Important Information - The company ended the year with $39 million in cash and investments, aligning with guidance, and has $25 million of unused capacity under its debt facility [39] - The net cash burn for Q4 was $3 million, with expectations for higher burn in Q1 [40] Q&A Session Summary Question: What is being done to reduce the gap between placed and validated systems? - Management indicated that timing variations affect the validation process and expect to see improvements as they work with customers like Amgen [53][56] Question: What percentage of placed systems are within CDMOs, and how is that space evolving? - Management noted a strong value proposition for CDMOs and highlighted ongoing growth in this segment [58][60] Question: What are the key drivers for achieving the 20% gross margin target for 2026? - Key drivers include locked-in product cost reductions and expected increases in service revenue as validations progress [66][70] Question: How will the next-gen cloud-native software platform be integrated into devices? - The platform will be a complete rewrite of the application software, providing easier integration and potential future revenue from cloud services [96][100]

Investment Focus & Strategy - Insight invests across stages, from early-stage startups to post-IPO companies, with a history of 55 IPOs [2] - Insight provides expertise, access, and talent to help portfolio companies scale and grow [3] - Insight emphasizes helping companies build the best products and achieve their dreams [2][3] AI Adoption & Transformation - Insight runs an AI accelerator program to help portfolio companies keep up with the pace of change [4] - The AI accelerator program focuses on helping CEOs drive change in two areas: AI in the product and AI in the business [6] - The program is a six-month program with small cohorts of CEOs [6] - AI is augmenting people and making them more efficient [8] Talent Acquisition & M&A - Venture capital is also a domain for M&A, with the onsite team providing expertise to help companies make acquisitions for geographic expansion, new products, and talent acquisition [13] - Companies are using acquisitions to access AI-native talent [14] Industry Application - One portfolio company in the airline industry uses AI to analyze over 7,000 daily incidents, providing critical insights to keep aircraft safe and revenue flowing [9][10]